High cisplatin dose increases risk of metabolic syndrome in survivors of testicular cancer
This article has no abstract so we have provided the first paragraph of the full text.
Although advances in the treatment of testicular cancer have markedly increased life expectancy, a number of reports have indicated an increased risk of cardiovascular disease in survivors, possibly mediated through the metabolic syndrome. Haugnes et al. examined the prevalence of metabolic syndrome in a national follow-up study involving 1,135 survivors of testicular cancer. Median follow-up was 11.1 years.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.